Table 3.
Clinical use of PSMA ligands (Oct 2019)
| 18F-PSMA ligands | Organization or company | Clinical phase | |
| 1 | 18F-DCFPyL | Progenics Pharmaceuticals | Phase 3 |
| 2 | 18F-PSMA-1007 | ABX | Clinical study |
| 3 | 18F-CTT1057 | Novartis (AAA) | Phase 1 |
| 4 | 18F-rhPSMA-7.3 | Blue Earth Diagnostics | Phase 1 |
| 5 | 18F-FSU-880 | Kyoto University | Phase 2 |
| 68 Ga-PSMA ligands | Organization or company | Clinical phase | |
| 1 | 68Ga-PSMA-11 | Telix Pharmaceuticals | Phase 3 |
| 2 | 68Ga-PSMA-617 | Novartis (Endocyte) | Clinical study |
| 3 | 68Ga-PSMA-I&T | Technical University of Munich | Clinical study |
| PSMA ligands for RLT | Organization or company | Clinical phase | |
| 1 | 177Lu-PSMA-617 | Novartis (Endocyte) | Phase 3 |
| 2 | 225Ac-PSMA-617 | Novartis (Endocyte) | Phase 1 |
| 3 | 177Lu-TX591 | Telix Pharmaceuticals | Phase 2 |
| 4 | 177Lu-PSMA-R2 | Novartis (AAA) | Phase 1/2 |
| 5 | 227Th-PSMA-TTC | Bayer | Phase 1 |
Abbreviation: RLT, radioligand therapy.